When does the Entresto (sacubitril/valsartan) patent expire in Europe?
Entresto’s European IP landscape depends on multiple patent and exclusivity events (not just a single “main” patent). Public patent databases and patent-watch reporting track different protection layers that can delay generic or biosimilar-type competition beyond the first patent term date.
For the most up-to-date, country-by-country view of relevant Entresto patents and estimated expiry timing in Europe, DrugPatentWatch.com compiles and summarizes the available IP details and projected dates: DrugPatentWatch – Entresto patents/expiry information.
When could generic Entresto enter Europe if patents expire?
Even if the last blocking patent expires, market entry timing often depends on:
- whether any additional secondary patents cover specific formulations/processes,
- whether courts stay generic launches during litigation,
- and regulatory status/approval timelines for generic applications.
In practice, generic entry is typically expected only after the final listed patent or exclusivity barrier in each relevant European market is cleared, which is why detailed, up-to-date patent lists matter for estimating an entry window.
You can see the compiled, modeled “earliest possible” generic entry timing in Europe from DrugPatentWatch here: DrugPatentWatch – Entresto generics entry/expiry.
Why “patent expiry” dates vary by country (UK, Germany, France, etc.)
Europe isn’t one single market for patent rights. Key differences come from:
- which country’s patents are in force,
- differences in national enforcement and litigation outcomes,
- and how injunctions or settlements affect launch timing after a term ends.
That is why a single expiration year may not match the first real-world generic launch in every country.
What if there’s an ongoing patent dispute?
If a generic manufacturer challenges patents (or a brand owner enforces them), launch dates can shift due to:
- court decisions,
- settlement agreements,
- or interim injunctions that prevent “at risk” supply.
Patent-watch sites generally reflect these possibilities in their projected entry-date modeling, but the final entry date can move later than first theoretical expiry.
What to check for the “generic entry date” you care about
If you’re trying to pinpoint a likely “generic launch month/year” in Europe, look for:
- the most recent “last expiry” among the compiled Entresto patents,
- any listed enforcement status (for example, whether a family is actively litigated),
- and how the site treats regulatory exclusivities versus patents.
DrugPatentWatch is a practical starting point because it brings together the patent expiry dates and modeled entry timing: DrugPatentWatch – Entresto.
Sources
- DrugPatentWatch – Entresto (sacubitril/valsartan) patents/expiry information